General
Preferred name
VORICONAZOLE
Synonyms
Voriconazole (Vfend) ()
VORICONAZOLE137234-62-9 ()
(±)-Voriconazole ()
UK-109496 ()
(±)-UK-109496 ()
Vfend,UK-109496 ()
Voriconazole (UK-109496) ()
(¡À)-Voriconazole ()
Voriconazole-d3 ()
NSC-759888 ()
Vfend ()
Voriconazole accord ()
UK-109,496 ()
Voriconazole hikma (previously voriconazole hospira) ()
Voriconazol ()
(¡À)-UK-109496 ()
P&D ID
PD001669
CAS
137234-62-9
188416-29-7
1217661-14-7
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2002
Drug indication
Invasive aspergillosis
Aspergillosis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-¦Á-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes[1][2].
DESCRIPTION
(¡À)-Voriconazole ((¡À)-UK-109496) is a relative configuration of Voriconazole (HY-76200). Voriconazole is an antifungal agent[1].
DESCRIPTION
Triazole antifungal agent
(Tocris Bioactive Compound Library)
DESCRIPTION
Voriconazole is a triazole antifungal medication used to treat serious fungal infections, including invasive candidiasis, invasive aspergillosis, and emerging fungal infections. Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
6
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
349.12
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.18
TPSA
76.72
Fraction CSP3
0.25
Chiral centers
2.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Primary Target
Miscellaneous Compounds
Indication
esophageal candidiasis, aspergillosis, skin infections
Target
CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1
CYP51 inhibitor
Bacterial
Fungal
Fungal,P450 (e.g. CYP17)
MOA
Cytochrome P450 inhibitor
Therapeutic Class
Antifungal Agents
Pathway
Anti-infection
Source data
